NCT06252220

First in Human Study in Subjects With Obesity, But Otherwise Healthy

A Phase 1, Randomized, Placebo-Controlled, Double-Blind First in Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DA-1726 in Participants With Obesity.

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 139 (estimated)
• Sponsor: NeuroBo Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.

Detailed description

This is a Phase 1, randomized, placebo-controlled, double-blind, sequential parallel group study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in adult participants (aged 18 to 65 years) with obesity (BMI ≥30 - 45 kg/m2). DA-1726 will be administered via subcutaneous (SC) injection within the clinic setting.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	DA-1726	Active
DRUG	Placebo to DA-1726	Placebo

Timeline

• Start date: 2024-03-25
• Primary completion: 2026-11-09
• Completion: 2026-11-09
• First posted: 2024-02-09
• Last updated: 2026-04-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study